Levomilnacipran

• Major Depressive Disorder
• Depression Treatment
• SNRI Antidepressant Therapy
• Adult Depression

Levomilnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant used for the treatment of major depressive disorder in adults. As the more active enantiomer of milnacipran, levomilnacipran offers potent norepinephrine reuptake inhibition that may benefit patients with fatigue and lack of motivation.

Mechanism of Action

Levomilnacipran is the more pharmacologically active enantiomer of the racemic compound milnacipran. It inhibits the reuptake of both serotonin and norepinephrine by binding to their respective transporter proteins. Unlike some other SNRIs, levomilnacipran has greater selectivity for norepinephrine reuptake inhibition over serotonin (approximately 2:1 ratio), which may contribute to its effects on energy, motivation, and concentration. The increased synaptic concentrations of both neurotransmitters in brain regions associated with mood regulation contribute to its antidepressant effects.

Available Formulations

Levomilnacipran is available as extended-release capsules in 20 mg, 40 mg, 80 mg, and 120 mg strengths. The capsules should be swallowed whole and should not be opened, chewed, or crushed. The medication can be taken with or without food.

Medical Uses

Levomilnacipran is FDA-approved for the treatment of major depressive disorder (MDD) in adults. Clinical trials demonstrated significant improvement in depression symptoms, including measures of functional impairment and physical symptoms. Its norepinephrine activity may be particularly beneficial for patients with prominent fatigue, low energy, or difficulty concentrating.

Dosing Guidelines

The recommended starting dose is 20 mg once daily for 2 days, followed by an increase to 40 mg once daily. Based on efficacy and tolerability, the dose may be increased in increments of 40 mg at intervals of 2 or more days. The recommended dose range is 40-120 mg once daily; maximum dose is 120 mg once daily. For patients with moderate renal impairment (CrCl 30-59 mL/min), maximum dose is 80 mg once daily; for severe impairment (CrCl 15-29 mL/min), maximum is 40 mg once daily.

Important Safety Information

Levomilnacipran carries a boxed warning for increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults with major depressive disorder. Monitor all patients for clinical worsening and suicidal ideation. Serotonin syndrome can occur, especially with concurrent serotonergic drugs, and can be life-threatening. Other serious risks include elevated blood pressure and heart rate, activation of mania/hypomania, abnormal bleeding, narrow-angle glaucoma, and urinary hesitation and retention. Abrupt discontinuation can cause withdrawal symptoms.

Drug Interactions

MAOIs are contraindicated due to serotonin syndrome risk; allow 14-day washout in either direction. Other serotonergic drugs increase serotonin syndrome risk. Drugs that increase blood pressure or heart rate may have additive effects. CYP3A4 inhibitors may increase levomilnacipran exposure modestly. Strong CYP3A4 inhibitors should not be used at doses above 80 mg/day. Drugs affecting hemostasis (NSAIDs, aspirin, anticoagulants) may increase bleeding risk.

Special Populations

There are no adequate studies in pregnant women. Neonates exposed to SNRIs late in the third trimester may experience complications. Use during pregnancy only if benefit justifies risk. Levomilnacipran is excreted in rat milk; decide whether to discontinue breastfeeding or the drug. Safety and efficacy have not been established in pediatric patients. Clinical trials did not include sufficient numbers of patients 65 and older; elderly patients may be at increased risk for hyponatremia. Dose adjustment is required for renal impairment; the medication is not recommended for end-stage renal disease.